Promoting resilience in Black women with metastatic breast cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This pilot interventional study evaluates the effectiveness of the Promoting Resilience in Women with Breast Cancer (PRISM) intervention on resilience and patient-reported outcomes in Black women diagnosed with metastatic breast cancer. The study aims to assess changes from baseline to post-intervention, focusing on the unique challenges faced by this population due to adverse social determinants of health. It also seeks to determine the feasibility and acceptability of the intervention among participants. By addressing both psychological and social factors, the study hopes to improve quality of life for these patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Written informed consent obtained to participate in the study and HIPAA authorization for release of personal health information.
* Participants are willing and able to comply with study procedures based on the judgement of the investigator.
* Male and female patients of age \>18 years.
* Pathologic diagnosis of metastatic breast cancer within 182 days prior to enrollment date.
* Able to answer surveys and participate in counseling sessions in English (the patient's first language is not required to be English).
* Indicate intent to receive ongoing cancer care at the enrolling institution.

Exclusion Criteria:

Individuals meeting any of the following exclusion criteria will be excluded from study participation.

* Patient unwilling or unable to complete surveys via one of the following methods: (a) paper survey completed in clinic or mailed directly to patient's home address, including a pre-addressed, pre-stamped return envelope in the mailed survey packet, or (b) electronic survey links sent via emails or text link on a mobile device, tablet, laptop, or desktop computer.
* Patient unwilling or unable to provide verbal or signed consent to participate.
* Participant cannot read English.
* Patient has permanently discontinued cancer-directed therapy or does not intend to receive any cancer-directed therapy, is receiving home or residential hospice care, is hospitalized, or is described as likely to die within 90 days or actively dying in last provider documentation, at the time of enrollment.

Where it's running

• The University of Alabama
  Birmingham, Alabama, United States Recruiting
• University of North Carolina
  Chapel Hill, North Carolina, United States Recruiting

Study contacts

• Principal investigator: Katie Reeder-Hayes, MD, MBA, MSCR — UNC Lineberger Comprehensive Cancer Center
• Study coordinator: Erin Laurie-Zehr
• Email: erin_laurie@med.unc.edu
• Phone: (919)-445-4941

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• PRT13722 in advanced HR+/HER2- breast cancer

  This early study tests PRT13722, by itself and with standard therapies, to see if it is safe and has any signs of activity in adults with HR+/HER2- breast cancer who have progressed on prior treatments.

  Recruiting Phase 1 Prelude Therapeutics Incorporated · Maumee, Ohio · NCT07905001

• Entinostat with Pyrotinib and Endocrine Therapy in HER2-positive, HR-positive Advanced Breast Cancer after Trastuzumab Failure

  This study tests whether adding entinostat to pyrotinib and hormone therapy is safe and helps patients with advanced HR+/HER2+ breast cancer who progressed after trastuzumab.

  Recruiting Phase 1/2 Tianjin Medical University Cancer Institute and Hospital · Tianjin, Tianjin Municipality · NCT07708194

• UGT1A1 gene and side effects from certain antibody-drug treatments for advanced breast cancer

  This project will test whether common UGT1A1 gene variants explain who gets worse side effects from antibody-drug conjugates (sacituzumab-govitecan, trastuzumab-deruxtecan, or datopotamab-deruxtecan) in adults with advanced breast cancer.

  Recruiting Fundación Pública Andaluza para la Investigación Biomédica Andalucía Oriental · Granada, Granada · NCT07582887

• Generative AI Education Tool for Breast Cancer Care

  Researchers are testing an AI-powered teaching tool to help adults with breast cancer understand their care while receiving treatment from UCSF physicians.

  Recruiting University of California, San Francisco · San Francisco, California · NCT07512271

• Pulsed Electric Field Ablation for Metastatic Breast Cancer

  This trial tests a one-time pulsed electric field ablation to treat superficial metastatic breast cancer lesions in adults, guided by imaging.

  Recruiting University of California, San Francisco · San Francisco, California · NCT07487844

• Adaptive biomarker-driven therapies for metastatic breast cancer

  This trial tests whether matching targeted drug combinations to tumor biomarkers helps people with ER+/HER2- or triple-negative metastatic breast cancer who are starting second-line treatment.

  Recruiting at 4 sites Phase 2 UNC Lineberger Comprehensive Cancer Center · New Haven, Connecticut and 5 other locations · NCT07340541

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.